In a previous study, it was found that employing a pepsinogen I/II ratio below 2.3 and gastrin-17 levels exceeding 29.6 pmol/L serves as a definitive approach to distinguish autoimmune gastritis patients with gastric neuroendocrine tumors from those without [55]. This evidence concerns the gene GAST and autoimmune gastritis.